Childhood primary angiitis of the central nervous system following COVID-19 vaccination (BNT162b2/Pfizer-BioNtech): A case report.
COVID-19 vaccine
Childhood primary angiitis of the central nervous system
mRNA vaccine
methylprednisolone pulse therapy
vasculitis
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
medline:
2
10
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
ppublish
Résumé
Childhood primary angiitis of the central nervous system (cPACNS) is a vasculitis of unknown etiology that is confined to the central nervous system (CNS) and can lead to repeated cerebral infarctions if left untreated. Several cases of cPACNS after COVID-19 have been reported. Herein, we present a case of post-vaccination cPACNS. A 9-year-old healthy boy presented with persistent headache and fever after receiving the second COVID-19 vaccine (BNT162b2/Pfizer-BioNtech) dose. Brain magnetic resonance angiography (MRA) performed on the sixth day of symptom onset after vaccination revealed stenosis of the left middle cerebral artery; the patient was referred to our department on the 12th day of symptom onset. Blood tests indicated only minimal evidence of inflammation, whereas cerebrospinal fluid examination indicated pleocytosis. Brain magnetic resonance imaging (MRI) revealed vascular wall thickening and contrast enhancement of the artery with worsened stenosis. We diagnosed the patient as having cPACNS and treated him with three courses of methylprednisolone pulse therapy. The headaches and fever disappeared with improvement of vascular stenosis. The patient has been in remission for more than 1 year since cPACNS onset. This is the first report of a case of cPACNS after mRNA vaccination for COVID-19. Most previous cases of COVID-19-associated cPACNS presented with ischemic stroke. However, the present case could be treated for vasculitis prior to stroke and thus had a favorable prognosis. The mRNA vaccine for COVID-19 differs from other existing vaccines, and further accumulation of data of cases is required to determine adverse CNS reactions.
Identifiants
pubmed: 37772503
doi: 10.1080/21645515.2023.2261167
pmc: PMC10543344
doi:
Substances chimiques
BNT162 Vaccine
0
COVID-19 Vaccines
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2261167Références
Autops Case Rep. 2021 May 06;11:e2021262
pubmed: 34307223
Eur J Paediatr Neurol. 2022 Sep;40:40-43
pubmed: 35933829
Radiology. 2020 Nov;297(2):E274-E275
pubmed: 32484418
Pediatrics. 2021 Mar;147(3):
pubmed: 33277353
Pediatr Neurol. 2022 Feb;127:1-5
pubmed: 34864371
Curr Opin Neurol. 2020 Feb;33(1):37-46
pubmed: 31815778
Clin Immunol. 2021 Aug;229:108786
pubmed: 34147649
N Engl J Med. 2022 Jan 6;386(1):35-46
pubmed: 34752019
Brain Dev. 2020 Oct;42(9):675-679
pubmed: 32622763
Signal Transduct Target Ther. 2021 Sep 6;6(1):337
pubmed: 34489403
Int J Stroke. 2023 Aug;18(7):765-772
pubmed: 36691675
Semin Arthritis Rheum. 2022 Aug;55:152047
pubmed: 35709649
AJNR Am J Neuroradiol. 2020 Dec;41(12):2348-2350
pubmed: 32816770
Front Pediatr. 2020 Jul 03;8:281
pubmed: 32719754
Semin Pediatr Neurol. 2022 Dec;44:100995
pubmed: 36456035
Front Pediatr. 2021 Mar 26;9:654537
pubmed: 33842414
Front Neurol. 2021 Apr 08;12:606617
pubmed: 33897582
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Neurosci Lett. 2021 Jan 19;743:135564
pubmed: 33352277